Join
Live feed
·
PRReleasevia Quantisnow
Tharimmune Inc. logo

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab

ByQuantisnow·Wall Street's wire, on your screen.
THAR· Tharimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track THAR (Tharimmune Inc.) and more on Quantisnow.